The company announced that it will cease development of Mosnodenvir, a drug candidate designed to be the first anti-viral treatment for dengue. It is unclear if another developer will license the ...

Progression to the phase 2b cohort follows recommendation of the Safety Review Committee (SRC) after it reviewed positive ...

According to the World Health Organization (WHO), there are about 390 million dengue infections globally in a year, with more ...

The drug, produced by the laboratory Takeda, targets “dengue virus 2” and protects ... and Medical Technology (Anmat) approved the treatment which is already available at private vaccination ...

Bangladesh reported its first dengue death of the year in 24 hours till Saturday morning (4 January). The death has been reported in the Dhaka North City Corporation, according to the Directorate ...